'Novo Nordisk chief executive Lars Fruergaard Jørgensen has set his eyes on another “gold mine”: trial data that could offer clues on why some people are more likely to gain weight, and perhaps even lead to the first drugs designed to prevent obesity.'

https://www.ft.com/content/63092b84-1ec6-42cf-85ba-f4578f31d3ab